| 70-gene signature as an aid to treatment decisions in early-stage breast cancer F Cardoso, LJ van’t Veer, J Bogaerts, L Slaets, G Viale, S Delaloge, ... New England Journal of Medicine 375 (8), 717-729, 2016 | 1859 | 2016 |
| Event-free survival with pembrolizumab in early triple-negative breast cancer P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kümmel, J Bergh, ... New England Journal of Medicine 386 (6), 556-567, 2022 | 598 | 2022 |
| Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program F Cardoso, JMS Bartlett, L Slaets, CHM Van Deurzen, ... Annals of Oncology 29 (2), 405-417, 2018 | 352 | 2018 |
| Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk … LE Elshof, K Tryfonidis, L Slaets, AE van Leeuwen-Stok, VP Skinner, N Dif, ... European journal of cancer 51 (12), 1497-1510, 2015 | 347 | 2015 |
| Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 … P Schmid, R Salgado, YH Park, E Muñoz-Couselo, SB Kim, J Sohn, SA Im, ... Annals of Oncology 31 (5), 569-581, 2020 | 321 | 2020 |
| 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age M Piccart, LJ van't Veer, C Poncet, JMNL Cardozo, S Delaloge, JY Pierga, ... The Lancet Oncology 22 (4), 476-488, 2021 | 231 | 2021 |
| Management of locally advanced breast cancer—perspectives and future directions K Tryfonidis, E Senkus, MJ Cardoso, F Cardoso Nature Reviews Clinical Oncology 12 (3), 147-162, 2015 | 164 | 2015 |
| Endocrine treatment in breast cancer: Cure, resistance and beyond K Tryfonidis, D Zardavas, BS Katzenellenbogen, M Piccart Cancer treatment reviews 50, 68-81, 2016 | 151 | 2016 |
| VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab+ chemotherapy vs. placebo+ chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kümmel, J Bergh, ... Annals of Oncology 32 (9), 1198-1200, 2021 | 146 | 2021 |
| Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives KC Aalders, K Tryfonidis, E Senkus, F Cardoso Cancer treatment reviews 53, 98-110, 2017 | 126 | 2017 |
| Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised … H Wildiers, K Tryfonidis, L Dal Lago, P Vuylsteke, G Curigliano, S Waters, ... The Lancet Oncology 19 (3), 323-336, 2018 | 109 | 2018 |
| Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials I Ghislain, E Zikos, C Coens, C Quinten, V Balta, K Tryfonidis, M Piccart, ... The Lancet Oncology 17 (7), e294-e304, 2016 | 102 | 2016 |
| Pathological characterisation of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program MA Vermeulen, L Slaets, F Cardoso, SH Giordano, K Tryfonidis, ... European Journal of Cancer 82, 219-227, 2017 | 98 | 2017 |
| The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches F Ades, K Tryfonidis, D Zardavas ecancermedicalscience 11, 2017 | 84 | 2017 |
| Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial M Ignatiadis, S Litière, F Rothe, S Riethdorf, C Proudhon, T Fehm, ... Annals of oncology 29 (8), 1777-1783, 2018 | 72 | 2018 |
| Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial G Viale, FA De Snoo, L Slaets, J Bogaerts, L van ’t Veer, EJ Rutgers, ... Breast cancer research and treatment 167, 123-131, 2018 | 64 | 2018 |
| Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial M Ignatiadis, B Rack, F Rothé, S Riethdorf, C Decraene, H Bonnefoi, ... European Journal of Cancer 63, 97-104, 2016 | 58 | 2016 |
| Event-free survival by residual cancer burden after neoadjuvant pembrolizumab+ chemotherapy versus placebo+ chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. L Pusztai, C Denkert, J O'Shaughnessy, J Cortes, RA Dent, HL McArthur, ... Journal of Clinical Oncology 40 (16_suppl), 503-503, 2022 | 48 | 2022 |
| Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program F Cardoso, J Bartlett, L Slaets, C van Deurzen, E van Leewen-Stok, ... Cancer Research 75 (9_Supplement), S6-05-S6-05, 2015 | 43 | 2015 |
| Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program SC Doebar, L Slaets, F Cardoso, SH Giordano, JMS Bartlett, K Tryfonidis, ... Modern Pathology 30 (4), 509-518, 2017 | 41 | 2017 |
